|
Title
|
Published
|
Price
|
|
Targeted Therapies in Oncology: A World Review
By: BioSeeker Group AB
Introduction
The dogma for treatment of cancer has changed, with the cytotoxic drugs used in chemotherapy regimes set to lose their dominance and be used alongside targeted therapies that are being developed with the
|
more...
|
10/9/2006
|
$4,158.00
|
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
By: BioSeeker Group AB
Executive Summary
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Non Small Cell Lung Cancer Therapeutics, Protein Kinase Inhibitors and Anti-angiogenesis and Vascular Targeting in
|
more...
|
10/9/2006
|
$2,898.00
|
|
Leukemia - A Therapeutic & Competitive Insight
By: BioSeeker Group AB
Introduction
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has
|
more...
|
10/6/2006
|
$1,638.00
|
|
Vascular Targeting and Anti-angiogenesis in Oncology: Drug Pipeline Update 2006
By: BioSeeker Group AB
Executive Summary
Avastin was the first angiogenesis inhibitor to reach the market upon its US FDA approval in 2004 for the treatment of colorectal cancer. Since then Genentech and Roche have undertaken a program
|
more...
|
8/21/2006
|
$1,979.00
|
|
Immunotherapy in Oncology: Gaining Momentum
By: BioSeeker Group AB
Introduction
The immunotherapy field in cancer has never been more potent than it is right now, including block buster drugs like Avastin, Erbitux, and Rituxan. Antibodies are making the headlines but cancer vaccines are
|
more...
|
8/4/2006
|
$2,065.00
|
|
Analytical Tool - Competitive Outlook on Cancer Vaccines
By: BioSeeker Group AB
"Analytical Tool - Competitive Outlook on Cancer Vaccines" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer vaccine R&D and business development. It is also a map
|
more...
|
8/4/2006
|
$4,092.00
|
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
By: BioSeeker Group AB
Executive Summary
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Protein Kinase Inhibitors (PKI), Antibodies and Vaccines in Oncology, which are all subjects to an
|
more...
|
8/3/2006
|
$2,898.00
|
|
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
By: BioSeeker Group AB
Executive Summary
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Melanoma Therapeutics, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number
|
more...
|
8/3/2006
|
$2,898.00
|
|
Competitive Outlook on Non-Antibody Based Cancer Vaccines
By: BioSeeker Group AB
Introduction
New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself
|
more...
|
8/3/2006
|
$1,638.00
|
|
Analytical Tool - The Commercial Success of Cancer Therapeutic Antibodies
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - The Commercial Success of Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody R&D and business development in
|
more...
|
6/29/2006
|
$4,092.00
|
|
Analytical Tool - Lymphoma Therapeutics & Competitive Insights
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Lymphoma Therapeutics & Competitive Insights" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. It is at the
|
more...
|
6/1/2006
|
$4,092.00
|
|
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
By: BioSeeker Group AB
Executive Summary
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Lymphoma, Protein Kinase Inhibitors and Therapeutic Antibodies, which are all subjects to an extensive number
|
more...
|
5/29/2006
|
$2,898.00
|
|
Lymphoma - A Therapeutic & Competitive Insight
By: BioSeeker Group AB
Introduction
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and
|
more...
|
5/29/2006
|
$1,638.00
|
|
Triple Progress Analysis - Melanoma, Colorectal & Lung Cancer
By: BioSeeker Group AB
Introduction
Novel therapeutic strategies are emerging in cancer treatment. Melanoma, colorectal and lung cancer are all cancer types subjected to a large potion of innovative drug candidates. In this 400 page report BioSeeker Group has
|
more...
|
3/29/2006
|
$2,898.00
|
|
Non-Antibody Based Cancer Vaccines: Drug Pipeline Update 2006
By: BioSeeker Group AB
The development of cancer vaccines has been a real roller-coaster, from the early excitement to the total disillusionment and now to the resurrection. Today, there are more than 170 companies developing more than 260 non-antibody
|
more...
|
3/20/2006
|
$1,979.00
|
|
Current and Future Therapies for Lung Cancer - A Therapeutic & Competitive Insight
By: BioSeeker Group AB
Introduction
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer
|
more...
|
3/14/2006
|
$1,638.00
|
|
Analytical Tool - Current & Future Lung Cancer Therapeutics
By: BioSeeker Group AB
Introduction
Analytical Tool - Current & Future Lung Cancer Therapeutics is a premium combo product of "Current and Future Therapies for Lung Cancer: A Therapeutic & Competitive Insight" and "Lung Cancer Drug Pipeline Update
|
more...
|
3/14/2006
|
$4,092.00
|
|
Analytical Tool - Analysis of Cancer Immunotherapy: The World Guide
By: BioSeeker Group AB
A significant advantage with BioSeeker Group CD-ROM searchable databases is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy
|
more...
|
3/13/2006
|
$7,735.00
|
|
Strategic Outlook on Protein Kinase Inhibitors in Oncology
By: BioSeeker Group AB
Introduction
Since the discovery that the v-Src oncogene encoded a protein kinase in 1978, kinases have become a targeted therapy strategy in oncology for the pharmaceutical industry. The perfect date between Gleevec and Chronic
|
more...
|
2/20/2006
|
$1,638.00
|
|
European Biotech Industry Guide 2006, 4th Ed.
By: BioSeeker Group AB
Executive Summary
This exciting intelligence CD-ROM on European biotech industry has become better, stronger and more intelligent in its 4th Edition. The 4th d Edition of "European Biotech Industry Guide" has not only been updated
|
more...
|
2/13/2006
|
$791.00
|
|
New Concepts in Cancer Therapeutics
By: BioSeeker Group AB
Introduction
In the world there are close to 25 million people living with cancer today, a figure that will probably increase to around 30 million people by 2020 .This publication is one of the most
|
more...
|
12/30/2005
|
$1,715.00
|
|
The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
By: BioSeeker Group AB
Executive Summary
Full Title: The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
Introduction
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks
|
more...
|
11/22/2005
|
$1,365.00
|
|
Superficial Bladder Cancer - Current Mangement and Future Trends
By: BioSeeker Group AB
Executive Summary
Superficial bladder cancers (SBC) comprise tumours with low aggressiveness but a high recurrence rate as well as lesions with a high risk of progression. All SBC are amenable to intravesical therapy and treatment
|
more...
|
11/1/2005
|
$903.00
|
|
World Guide to Bionanotechnology Industry and its Progression, 2nd ED
By: BioSeeker Group AB
Executive Summary
Nanotechnology, or the science of the small, holds enormous promise across all industries, not at least in life science. Since mid 90th there has been increasing intersection of two important scientific fields, nanotechnology
|
more...
|
10/24/2005
|
$699.00
|
|
Analytical Tool - Current & Future Therapies for Colorectal Cancer
By: BioSeeker Group AB
Executive Summary
"Analytical Tool - Current & Future Therapies for Colorectal Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal (CRC) R&D and business development.
|
more...
|
9/19/2005
|
$4,092.00
|
|
Title
|
Published
|
Price
|
(0 items)
